These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22868084)

  • 1. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.
    Loven D; Hasnis E; Bertolini F; Shaked Y
    Drug Discov Today; 2013 Feb; 18(3-4):193-201. PubMed ID: 22868084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
    Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose metronomic chemotherapy: a systematic literature analysis.
    Lien K; Georgsdottir S; Sivanathan L; Chan K; Emmenegger U
    Eur J Cancer; 2013 Nov; 49(16):3387-95. PubMed ID: 23880474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
    Kareva I; Waxman DJ; Lakka Klement G
    Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.
    Wu H; Xin Y; Zhao J; Sun D; Li W; Hu Y; Wang S
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):879-87. PubMed ID: 21290245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.
    Cramarossa G; Lee EK; Sivanathan L; Georgsdottir S; Lien K; Santos KD; Chan K; Emmenegger U
    Biomark Med; 2014; 8(6):893-911. PubMed ID: 25224945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts.
    Zhang M; Tao W; Pan S; Sun X; Jiang H
    Anticancer Drugs; 2009 Jun; 20(5):355-63. PubMed ID: 19318912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic scheduling: the future of chemotherapy?
    Gasparini G
    Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor endothelial cells as a potential target of metronomic chemotherapy.
    Kim JY; Kim YM
    Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
    Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
    Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
    Gnoni A; Silvestris N; Licchetta A; Santini D; Scartozzi M; Ria R; Pisconti S; Petrelli F; Vacca A; Lorusso V
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):46-61. PubMed ID: 25656744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
    André N; Padovani L; Pasquier E
    Future Oncol; 2011 Mar; 7(3):385-94. PubMed ID: 21417902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological aspects of cancer chemotherapy.
    Zitvogel L; Apetoh L; Ghiringhelli F; Kroemer G
    Nat Rev Immunol; 2008 Jan; 8(1):59-73. PubMed ID: 18097448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
    Arora G; Bairagi N; Chatterjee S
    Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.